South Africa Liver Cancer Therapeutics Market Report 2022 to 2030

South Africa Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, the South Africa Liver Cancer Therapeutics market is anticipated to reach a value of $75.7 Mn from $19 Mn in 2022, growing at a CAGR of 18.8 % during 2022-30. The Liver Cancer Therapeutics in South Africa is dominated by a few domestic pharmaceutical companies such as Aspen Pharmacare, Adcock Ingram, and AstraZeneca South Africa. The Liver Cancer Therapeutics market in South Africa is segmented into different types of cancer and different therapy type. Some of the major factors affecting the South Africa Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10ZAPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Dr. Vishwa Modhia

Buy Now

South Africa Liver Cancer Therapeutics Analysis Summary

By 2030, the South Africa Liver Cancer Therapeutics market is anticipated to reach a value of $75.7 Mn from $19 Mn in 2022, growing at a CAGR of 18.8 % during 2022-30.

South Africa is an upper-middle-income, developing country located at the southern tip of the African continent. The main risk factors for liver cancer in South Africa include chronic hepatitis B and C infections, excessive alcohol consumption, obesity, and diabetes. About 12% of the estimated cancers in 2020 in South Africa, were liver cancers attributed to alcohol drinking. According to the most recent WHO data published in 2020, the number of people dying from liver cancer in South Africa reached 2,383, accounting for 0.52 % of all deaths. South Africa ranks 87th in the world with an age-adjusted death rate of 5.46 per 100,000 population. In South Africa, liver cancer is the fourth most frequent malignancy, accounting for 4.6 % of all cancer cases.

South Africa is an active participant in clinical trials for the treatment of liver cancer. The country is a member of the African Organization for Cancer Research and Training, which promotes cancer research and clinical trials in Africa. South Africa’s government spent 4.6 % of its GDP on healthcare in 2020.

South Africa Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The South African government has started a number of steps to reduce the country's rising incidence of liver cancer. The National Cancer Control Plan, which attempts to lower the cancer burden in South Africa, and the Expanded Program on Immunization, which provides free hepatitis B immunizations to children, are two of these projects. South Africa's healthcare infrastructure is well-developed, with both public and private healthcare facilities offering liver cancer treatments. With a large and young population, South Africa is a regional economic and political force. These aspects could boost South Africa's Liver Cancer Therapeutics market.

Market Restraints

South Africa has a scarcity of healthcare staff, particularly in specialised disciplines such as oncology. This may limit patients with liver cancer's access to specialised care. Access to liver cancer treatments in South Africa may be limited for some individuals due to variables such as cost and geographical constraints. These factors may deter new entrants into the South Africa Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Aspen Pharmacare: Aspen Pharmacare is a leading pharmaceutical company in South Africa that is active in the liver cancer therapeutics market. The company offers a range of drugs for the treatment of liver cancer, including chemotherapy drugs, immunotherapy drugs, and targeted therapy drugs
Adcock Ingram: Adcock Ingram is a major pharmaceutical company in South Africa that is active in the liver cancer therapeutics market. The company offers a range of drugs for the treatment of liver cancer, including chemotherapy drugs and targeted therapy drugs
Roche South Africa
Pfizer South Africa
AstraZeneca South Africa

Recent Notable Updates

March 2023: AstraZeneca announced that a mid-stage trial of their cancer medication Enhertu, co-developed with Daiichi Sankyo, yielded good results in patients with multiple HER2-expressing advanced solid tumours. The ongoing DESTINY-PanTumor02 Phase II trial is evaluating Enhertu's efficacy and safety in patients with locally advanced or metastatic previously treated solid tumours that are not curable, including cervical, ovarian, pancreatic, and uncommon malignancies.

Healthcare Policies and Reimbursement Scenarios

In South Africa, the regulation and reimbursement of liver cancer treatments and therapies are overseen by the Medicines Control Council (MCC) and the South African Health Products Regulatory Authority (SAHPRA). The reimbursement of liver cancer treatments and therapies in South Africa is primarily provided by medical aid schemes and private health insurance companies. The South African government also provides limited reimbursement for liver cancer treatments through the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.